title: Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury.
abstract: The role of recurrent platelet aggregation in the development of neointimal proliferation of coronary arteries was explored in this study, and the hypothesis was evaluated that recurrent platelet aggregation and the consequent frequency and severity of cyclic coronary blood flow variations are important pathophysiologic factors in the subsequent development of neointimal proliferation. In 24 chronically instrumented dogs, variable degrees of coronary artery neointimal proliferation were observed 3 weeks after mechanical injury of the arterial endothelium and the placement of an external coronary artery constrictor. The severity of neointimal proliferation at 21 days was closely related to the frequency and severity of cyclic coronary blood flow variations during the initial 7 days after instrumentation of the animals, itself a manifestation of recurrent platelet aggregation and dislodgement. Pharmacological therapy with a dual thromboxane A2 synthetase inhibitor and receptor antagonist and with a serotonin S2 receptor antagonist frequently was successful in abolishing cyclic blood flow variations and in retarding neointimal proliferation.
authors.affiliation: Department of Internal Medicine, University of Texas Medical School, Houston 77030.
authors.forename: J T
authors.initials: JT
authors.lastname: Willerson
authors.forename: S K
authors.initials: SK
authors.lastname: Yao
authors.forename: J
authors.initials: J
authors.lastname: McNatt
authors.forename: C R
authors.initials: CR
authors.lastname: Benedict
authors.forename: H V
authors.initials: HV
authors.lastname: Anderson
authors.forename: P
authors.initials: P
authors.lastname: Golino
authors.forename: S S
authors.initials: SS
authors.lastname: Murphree
authors.forename: L M
authors.initials: LM
authors.lastname: Buja
mesh_terms: D000818:Animals; D001794:Blood Pressure; D002455:Cell Division / Q000187:drug effects; D003327:Coronary Disease / Q000473:pathology / Q000503:physiopathology*; D003331:Coronary Vessels / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology*; D004285:Dogs; D004730:Endothelium, Vascular / Q000293:injuries / Q000473:pathology / Q000503:physiopathology*; D004873:Ergolines / Q000494:pharmacology; D007650:Ketanserin / Q000494:pharmacology; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology*; D010974:Platelet Aggregation; D012702:Serotonin Antagonists / Q000494:pharmacology
chemical_list: D004873:Ergolines; D012702:Serotonin Antagonists; D007650:Ketanserin; C032663:LY 53857